NCT04493541Afimetoranafimetoran-treatedCutaneous lupus erythematosusCLE
…e and well tolerated in patients with CLE in a phase 1b trial ( NCT04493541). Here, we describe clinical disease activity and systemic and …
1articles mentioning funders
1funder mentions
1distinct funders extracted
0%of mentions human-reviewed
Active filtersEntity: NCT04493541 ×
NCT04493541
This funder is selected. Its supporting articles are shown below.